炎症性肠病患者血栓形成机制及抗凝治疗现状  

Thrombotic mechanism and anticoagulant therapy in inflammatory bowel disease patients

作　　者：甘冠华[1] 杨丽敏[1] 王进[1] 

机构地区：[1]郑州大学第一附属医院消化内科,河南省郑州市450052

出　　处：《世界华人消化杂志》2016年第2期236-241,共6页World Chinese Journal of Digestology

摘　　要：血栓栓塞作为炎症性肠病(inflammatory bowel disease,IBD)的一种肠外表现越来越受到关注,约1%-8%的IBD患者存在血栓栓塞,而进行黏膜活检证实的血栓发生率可高达41%.尽管已有较多既往研究证实血栓栓塞可威胁IBD患者的生命,但在日常临床工作中这种肠外表现仍常常被忽视.IBD患者合并血栓栓塞受多种因素影响,且与炎症状态相关,但其具体机制尚不完全明确.本文旨在综述目前IBD患者血栓形成的病理生理机制及抗凝治疗的研究概况,呼吁在控制IBD炎症活动的同时,亦注重血栓栓塞的预防.Thromboembolism （TE） in inflammatory bowel disease （IBD） is an increasingly noted extra-intestinal manifestation with high morbidity （about 1%-8%）, and the incidence rate can reach 41% by mucosal biopsy. Although TE is a life-threatening complication of IBD, this complication is often overlooked. To date, the mechanism behind this prothrombotic state encountered in IBD patients is not fully understood, and it is multifactorial and related to the inflammatory state. In this review, we provide an overview of the current understanding of thrombotic mechanism and anticoagulant therapy in IBD. While controlling the activity of the disease with appropriate therapy, thromboembolism prophylaxis should be considered.

关 键 词：炎症性肠病 血栓 机制 抗凝治疗 

分 类 号：R574[医药卫生—消化系统]